Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

NCT03652441 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT03652441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03652441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Lead sponsor
University of Cologne
Phase
Phase 2
Overall status
Completed
Start date
November 13, 2019
Completion date
January 25, 2025
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma